ATE136907T1 - Neue insulinanaloge geeignet für die transdermale anwendung - Google Patents

Neue insulinanaloge geeignet für die transdermale anwendung

Info

Publication number: ATE136907T1
Authority: AT; Austria
Prior art keywords: insulin analogues; new insulin; transdermal use; analogues suitable; molecule
Prior art date: 1991-01-22

Application number

AT92903864T

Other languages

English (en)

Inventor

Jens Jorgen Veilgaard Brange

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-22

Filing date

1992-01-22

Publication date

1996-05-15

1992-01-22 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1996-05-15 Application granted granted Critical

1996-05-15 Publication of ATE136907T1 publication Critical patent/ATE136907T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 3
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 2
125000000539 amino acid group Chemical group 0.000 abstract 1
230000007935 neutral effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Emergency Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT92903864T 1991-01-22 1992-01-22 Neue insulinanaloge geeignet für die transdermale anwendung ATE136907T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK010191A DK10191D0 (da)	1991-01-22	1991-01-22	Hidtil ukendte peptider

Publications (1)

Publication Number	Publication Date
ATE136907T1 true ATE136907T1 (de)	1996-05-15

Family

ID=8089747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92903864T ATE136907T1 (de)	1991-01-22	1992-01-22	Neue insulinanaloge geeignet für die transdermale anwendung

Country Status (9)

Country	Link
US (1)	US5597796A (de)
EP (1)	EP0568594B1 (de)
JP (1)	JPH06506444A (de)
AT (1)	ATE136907T1 (de)
AU (1)	AU1190292A (de)
CA (1)	CA2100565A1 (de)
DE (1)	DE69210011T2 (de)
DK (1)	DK10191D0 (de)
WO (1)	WO1992012999A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2087087C (en) *	1992-01-22	2000-07-18	Burton H. Sage, Jr.	Molecules for iontophoretic delivery
US5747453A (en) *	1995-06-06	1998-05-05	Alza Corporation	Method for increasing the electrotransport flux of polypeptides
IT1285405B1 (it)	1995-06-06	1998-06-03	Alza Corp	Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5807315A (en) *	1995-11-13	1998-09-15	Minimed, Inc.	Methods and devices for the delivery of monomeric proteins
US6333189B1 (en)	1996-06-06	2001-12-25	Alza Corporation	Method of making an electrotransport device
US5857994A (en) *	1996-10-01	1999-01-12	Becton, Dickinson And Company	Awakenable iontophoretic/delivery device for reducing electrical sensation upon application thereof
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1028706B1 (de) *	1997-11-12	2003-07-09	Alza Corporation	Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport
US6562942B1 (en) *	1999-02-23	2003-05-13	Neurocrine Biosciences, Inc.	Methods for treatment of diabetes using peptide analogues of insulin
US6406455B1 (en) *	1998-12-18	2002-06-18	Biovalve Technologies, Inc.	Injection devices
AU767510B2 (en) *	1999-02-18	2003-11-13	Valeritas, Inc.	Electroactive pore
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
NZ519403A (en) *	2001-06-21	2005-03-24	Pfizer Prod Inc	Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
JP4033382B2 (ja) *	2002-04-08	2008-01-16	久光製薬株式会社	インスリン投与装置
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
EP1991575A1 (de) *	2006-02-21	2008-11-19	Novo Nordisk A/S	Einkettige insulinanaloga und pharmazeutische formulierungen daraus
US8796205B2 (en)	2006-05-09	2014-08-05	Novo Nordisk A/S	Insulin derivative
EP2015770B1 (de) *	2006-05-09	2012-09-26	Novo Nordisk A/S	Insulinderivate
ES2542146T3 (es)	2006-07-31	2015-07-31	Novo Nordisk A/S	Insulinas extendidas PEGiladas.
PT2074141T (pt) *	2006-09-22	2016-11-10	Novo Nordisk As	Análogos de insulina resistentes a proteases
ES2563038T3 (es)	2007-04-30	2016-03-10	Novo Nordisk A/S	Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
JP2009067766A (ja) *	2007-09-12	2009-04-02	Kosumedei Seiyaku Kk	経皮吸収促製剤及びそれを用いた経皮吸収システム
KR20100111683A (ko)	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
KR20100111682A (ko)	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
CN101970477B (zh)	2008-03-14	2014-12-31	诺沃-诺迪斯克有限公司	蛋白酶稳定的胰岛素类似物
PL2910570T3 (pl)	2008-03-18	2017-06-30	Novo Nordisk A/S	Stabilizowane względem proteaz, acylowane analogi insuliny
LT3228320T (lt)	2008-10-17	2020-03-10	Sanofi-Aventis Deutschland Gmbh	Insulino ir glp-1 agonisto derinys
JP2012532177A (ja) *	2009-07-06	2012-12-13	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	熱及び振動安定性インスリン製剤
PE20121362A1 (es)	2009-11-13	2012-10-17	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
KR101772372B1 (ko)	2009-11-13	2017-08-29	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
WO2011121496A1 (en)	2010-03-31	2011-10-06	Wockhardt Limited	Composition comprising insulin and herbal oil for transdermal or transmucosal administration
EP2611458B1 (de)	2010-08-30	2016-09-21	Sanofi-Aventis Deutschland GmbH	Verwendung von ave0010 für die herstellung eines medikaments zur behandlung von diabetes mellitus typ 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en)	2011-08-29	2017-04-27	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2898730A1 (en) *	2012-01-20	2013-07-25	Case Western Reserve University	Glutamic acid-stabilized insulin analogues
KR20150002777A (ko)	2012-04-11	2015-01-07	노보 노르디스크 에이/에스	인슐린 제제
JP2016516728A (ja) *	2013-03-15	2016-06-09	ケースウェスタンリザーブユニバーシティＣａｓｅＷｅｓｔｅｒｎＲｅｓｅｒｖｅＵｎｉｖｅｒｓｉｔｙ	第２部位インスリン類似体
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
GB201321489D0 (en)	2013-12-05	2014-01-22	Chemical & Biopharmaceutical Lab Of Patras S A	Biologically active insulin derivatives
HRP20230470T1 (hr)	2014-12-12	2023-07-21	Sanofi-Aventis Deutschland Gmbh	Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
KR20190043609A (ko)	2016-09-06	2019-04-26	케미컬 앤드 바이오파마슈티컬 라보라토리즈 오브 파트라스 에스.에이.	프로인슐린 유도체
CN115154591B (zh)	2016-12-16	2023-04-14	诺和诺德股份有限公司	含胰岛素的药物组合物
EP3668892A1 (de)	2017-08-17	2020-06-24	Novo Nordisk A/S	Neuartige acylierte insulinanaloga und verwendungen dafür
EP3756679A1 (de)	2019-06-28	2020-12-30	Université de Genève	Zusammensetzungen zur verwendung in der behandlung von insulinmangelstörungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
DK257988D0 (da) *	1988-05-11	1988-05-11	Novo Industri As	Nye peptider
EP0425482B1 (de) *	1988-07-20	1993-08-18	Novo Nordisk A/S	Menschliche insulinanalage und zubereitungen daraus
JPH04502465A (ja) *	1988-12-23	1992-05-07	ノボ　ノルディスク　アクティーゼルスカブ	ヒトインシュリン類似物質
NZ232375A (en) *	1989-02-09	1992-04-28	Lilly Co Eli	Insulin analogues modified at b29
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain

1991
- 1991-01-22 DK DK010191A patent/DK10191D0/da not_active Application Discontinuation
1992
- 1992-01-22 CA CA002100565A patent/CA2100565A1/en not_active Abandoned
- 1992-01-22 JP JP4503787A patent/JPH06506444A/ja active Pending
- 1992-01-22 AT AT92903864T patent/ATE136907T1/de not_active IP Right Cessation
- 1992-01-22 WO PCT/DK1992/000019 patent/WO1992012999A1/en not_active Ceased
- 1992-01-22 DE DE69210011T patent/DE69210011T2/de not_active Expired - Fee Related
- 1992-01-22 AU AU11902/92A patent/AU1190292A/en not_active Abandoned
- 1992-01-22 EP EP92903864A patent/EP0568594B1/de not_active Expired - Lifetime
1994
- 1994-09-07 US US08/301,838 patent/US5597796A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69210011T2 (de)	1996-09-05
US5597796A (en)	1997-01-28
EP0568594A1 (de)	1993-11-10
CA2100565A1 (en)	1992-07-23
DE69210011D1 (de)	1996-05-23
EP0568594B1 (de)	1996-04-17
DK10191D0 (da)	1991-01-22
WO1992012999A1 (en)	1992-08-06
AU1190292A (en)	1992-08-27
JPH06506444A (ja)	1994-07-21

Publication	Publication Date	Title
ATE136907T1 (de)	1996-05-15	Neue insulinanaloge geeignet für die transdermale anwendung
FR2444064A1 (fr)	1980-07-11	Melange de polymere du chlorure de vinyle et de polyetherurethane a groupe amine tertiaire et/ou ammonium, notamment pour objet conforme a usage medical
ATE67505T1 (de)	1991-10-15	Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ID28003A (id)	2001-05-03	Turunan-turunan adamantana
BR9406363A (pt)	1996-02-27	Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
FI881876A7 (fi)	1988-10-23	Menetelmä neurologisten sairauksien hoitoon käytettävän koostumuksen valmistamiseksi.
DK0439042T3 (da)	1995-10-02	Anvendelse af farmaceutiske og kosmetiske præparater med blandingsmiceller
ATE66614T1 (de)	1991-09-15	Insulinzubereitung fuer nicht-parenterale verabreichung.
HUP9904023A2 (hu)	2000-03-28	Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
MX163955B (es)	1992-07-06	Composicion farmaceutica de dihidrocodeina e ibuprofen
FR2391730A1 (fr)	1978-12-22	Composition a base d'une resine styrene-divinylbenzene d'echange anionique portant des groupes ammonium quaternaire, destinee a fixer les acides biliaires
DE59303365D1 (de)	1996-09-05	Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
AU4626389A (en)	1990-06-26	Use of minoxidil for wound healing
ES2057004T3 (es)	1994-10-16	N-alcoxialquilamidas de hidroxiacidos y composiciones a base de las mismas para el tratamiento de la piel.
PT101444A (pt)	1994-10-31	Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
BE885251A (fr)	1981-03-16	Composition cosmetique contenant des derives d'ammonium bis-quaternaires a deux chaines lipophiles, destinee au traitement de matieres keratiniques
ITRM910730A0 (it)	1991-09-30	Composizioni farmaceutiche, per uso topico, contenenti "scavengers" diradicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali
CA2069638A1 (en)	1991-05-28	Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
DK0478631T3 (da)	1995-04-10	Målsøgende midler
ATE75404T1 (de)	1992-05-15	Verfahren zur herstellung nasaler loesungen enthaltend synthetisches human calcitonin.
IL101675A0 (en)	1992-12-30	Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
ATE128862T1 (de)	1995-10-15	Zusammensetzung zur lokalen anwendung.
EP0353474A3 (de)	1991-03-27	Glyzerin-Derivat und dessen pharmazeutische Verwendung
DK277387D0 (da)	1987-05-29	Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
ATE6639T1 (de)	1984-03-15	Ein gereinigtes polypeptid, ein verfahren zu dessen herstellung, dessen anwendung und das enthaltende pharmazeutische praeparat.

Legal Events

Date	Code	Title	Description
1996-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties